FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2022 · 1 min read
In brief
In brief
FOXR2, a testis-restricted transcription factor, is aberrantly activated through promoter hypomethylation in 8% of tumors across 70% of cancer types. The study demonstrates FOXR2 functions as a pan-cancer oncogene by hijacking ETS transcriptional circuits to promote tumor growth in both adult and pediatric malignancies.
Written by the GCMD Library team from the article.
Statements in this article
FOXR2 expression is normally restricted to the testis.
FOXR2 is aberrantly upregulated in 70% of all cancer types across more than 10,000 adult and pediatric cancer samples.
FOXR2 is aberrantly upregulated in 8% of all individual tumors.
78% of tumors aberrantly express FOXR2 through hypomethylation of a novel promoter.
The novel promoter is necessary for FOXR2 expression and proliferation in FOXR2-expressing cancer cells.
FOXR2 promotes tumor growth across multiple cancer lineages.
FOXR2 co-opts ETS family transcription circuits across cancers.